Publisher
Springer International Publishing
Reference35 articles.
1. Bennett, K. J., & Torrance, G. W. (1996). Measuring health state preferences and utilities: Rating scale, time trade-off, and standard gamble techniques. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials (2nd ed., pp. 253–265). Philadelphia: Lippincott-Raven Press.
2. Cole, B. F., Gelber, R. D., & Goldhirsch, A. (1995). A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group. Statistics in Medicine, 14(16), 1771–1784.
3. Cole, B. F., Gelber, R. D., Kirkwood, J. M., Goldhirsch, A., Barylak, E., & Borden, E. (1996). Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. Journal of Clinical Oncology, 14(10), 2666–2673.
4. Cole, B. F., Solal-Celigny, P., Gelber, R. D., Lepage, E., Gisselbrecht, C., Reyes, F., et al. (1998). Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making. Journal of Clinical Oncology, 16(7), 2339–2344.
5. Cole, B. F., Gelber, R. D., Gelber, S., Coates, A. S., & Goldhirsch, A. (2001). Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet, 358(9278), 277–286.